StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

Summit Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Summit Therapeutics's operating income for the twelve months ending Dec 31, 2024 was -$226.00M. For fiscal 2024 it was -$226.00M. The highest annual figure on record is $5.39M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$226.00M–
FY2023Dec 31, 2023-$609.65M–
FY2022Dec 31, 2022-$72.09M–
FY2021Dec 31, 2021-$86.19M-1699.3%
FY2019Jan 31, 2019$5.39M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2024CQ4 2024Dec 31, 2024-$65.61M–
Q3 FY2024CQ3 2024Sep 30, 2024-$58.38M–
Q2 FY2024CQ2 2024Jun 30, 2024-$59.62M–
Q1 FY2024CQ1 2024Mar 31, 2024-$42.39M–
Q4 FY2023CQ4 2023Dec 31, 2023-$36.21M–
Q3 FY2023CQ3 2023Sep 30, 2023-$20.49M–
Q2 FY2023CQ2 2023Jun 30, 2023-$15.79M–
Q1 FY2023CQ1 2023Mar 31, 2023-$537.15M–
Q4 FY2022CQ4 2022Dec 31, 2022-$20.30M–
Q3 FY2022CQ3 2022Sep 30, 2022-$16.94M–
Q2 FY2022CQ2 2022Jun 30, 2022-$12.69M–
Q1 FY2022CQ1 2022Mar 31, 2022-$22.16M–
Q4 FY2021CQ4 2021Dec 31, 2021-$26.05M–
Q3 FY2021CQ3 2021Sep 30, 2021-$19.49M–
Q2 FY2021CQ2 2021Jun 30, 2021-$23.73M–
Q1 FY2021CQ1 2021Mar 31, 2021-$16.92M–

More Summit Therapeutics figures

See a number that looks wrong?